Professor Giovannoni has received research grant support from Bayer-Schering Healthcare, Biogen-Idec, GW Pharma, Merck Serono, Merz, Novartis, Teva and Sanofi-Aventis. He has received personal compensation for participating on advisory boards, trial steering committees and trial data and safety monitoring boards from: Bayer-Schering Healthcare, Biogen-Idec, Eisai, Elan, Fiveprime, Genzyme, Genentech, GSK, GW Pharma, Ironwood, Merck-Serono, Novartis, Pfizer, Roche, Sanofi-Aventis, Synthon BV, Teva, UCB Pharma and Vertex Pharmaceuticals. As a principle we (Professor Giovannoni and his team) will attempt to declare all relevant conflicts of interest in relation to our postings. We realise the success of this blog depends on us being independent, or at least being transparent, and declaring our conflicts of interest in relation to specific postings.
Updated, 1st June 2011
MouseDoctor is founder/shareholder of a University Spinout Company aiming to develop new anti-symptomatic drugs for MS. He has provided ad-hoc consultancies and/or been the recipient of research grants/contracts from some of the companies mentioned above.
MouseDoctor2 as an inventor is a shareholder in the University Spinout Company and has undertaken contract research testing for some of the companies mentioned above.
